Voyager Therapeutics, Inc. (VYGR): Total Liabilities
$56.20M
As of 2025-12-31
$43.38M
As of 2026-06-30
-17.6%
3-year compound annual growth
-12.1%
5-year compound annual growth
-0.7%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $56.20M | -39.8% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $93.29M | -18.9% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $114.96M | +14.6% | 2025-03-11, Balance as of period end |
| 2022-12-31 | $100.34M | +1.6% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $98.80M | -7.9% | 2023-03-07, Balance as of period end |
| 2020-12-31 | $107.26M | -58.0% | 2022-03-08, Balance as of period end |
| 2019-12-31 | $255.25M | +95.5% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $130.58M | +159.0% | 2020-03-03, Balance as of period end |
| 2017-12-31 | $50.43M | -6.0% | 2019-02-26, Balance as of period end |
| 2016-12-31 | $53.64M | -11.2% | 2018-03-14, Balance as of period end |
| 2015-12-31 | $60.38M | +483.5% | 2017-03-15, Balance as of period end |
| 2014-12-31 | $10.35M | n/a | 2016-03-17, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $56.20M | -39.8% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $159.25M | -23.2% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $74.01M | -6.2% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $163.15M | +14.6% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $35.08M | -31.0% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $102.49M | -23.3% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $104.17M | -16.2% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $62.17M | -22.3% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $34.12M | +12.9% |
Compare VYGR, EDIT, SGMOQ, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗